CN1922191A - Crystal of oxacephem - Google Patents

Crystal of oxacephem Download PDF

Info

Publication number
CN1922191A
CN1922191A CNA2005800054157A CN200580005415A CN1922191A CN 1922191 A CN1922191 A CN 1922191A CN A2005800054157 A CNA2005800054157 A CN A2005800054157A CN 200580005415 A CN200580005415 A CN 200580005415A CN 1922191 A CN1922191 A CN 1922191A
Authority
CN
China
Prior art keywords
crystal
flomoxef
methyl acetate
methyl
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2005800054157A
Other languages
Chinese (zh)
Other versions
CN100509819C (en
Inventor
上仲正朗
野口耕一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN1922191A publication Critical patent/CN1922191A/en
Application granted granted Critical
Publication of CN100509819C publication Critical patent/CN100509819C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Provided are a hydrate of flomoxef or a solvate of flomoxef with methyl acetate, and crystals of these. They are advantageous from an environmental standpoint and for formulation into pharmaceutical preparations, etc. flomoxef.

Description

Crystal of oxacephem
[technical field]
[0001]
The present invention relates to oxacephem (Oxacephem) crystal, it can be used as biocide.
[background technology]
[0002]
Flomoxef with formula (I)
[Chemical formula 1]
Figure A20058000541500031
Can be used as the oxacephem biocide.Comprise the form that the freeze-dried preparation of its sodium salt can injection preparation and on market, obtain (trade(brand)name: Flumarin, Shionogi ﹠amp; Co., Ltd.).This class freeze-dried preparation makes as base substance and mixed chlorinated sodium and stablizer by using flomoxef.(seeing patent document 1).
The flomoxef crystal also is known, and for example, this crystal is in the presence of methylene dichloride and methyl-phenoxide, with Lewis acid (TiCl 4Or AlCl 3) handle the protected material of corresponding 4-carboxylic acid after, from ethyl acetate, crystallized out (see patent document 2, embodiment 3).In another well-known method, in the presence of methyl-phenoxide, used Lewis acid (SnCl at 4-carboxylic acid and the protected intermediate product of 3-terminal hydroxyl 4) do similar processing, crystallization from methylene dichloride and acetone afterwards (non-patent document 1).There is not the description of discovery about these crystalline forms.But,, obtain to contain the crystal of methylene dichloride by the method for in these files, describing according to the further research that the inventor did.
[0003]
[patent document 1]
Japanese unexamined patent publication JP-A 60-45514
[patent document 2]
Japanese unexamined patent publication JP-A 59-139385
[non-patent document 1]
The microbiotic magazine, (The Journal of Amtibiotics) (April, P466-476,1985)
[disclosure of the Invention]
[problem that this patent will solve]
[0004]
The flomoxef crystal that comprises methylene dichloride faces the difficulty that removes methylene dichloride with common drying means.As the formulation method in actual production, freeze-drying is used for sterilization equally, and it carries out according to described in the patent document 1, is not comprised the sodium salt of methylene dichloride thus.Yet freeze-drying needs high production cost usually, and, aspect maintenance of the equipment, need very big workload.So, need to use non-freeze dried method recently, as to the more effective commercial run of injection sterilization preparation as much as possiblely.Do not comprise at flomoxef under the situation of methylene dichloride, flomoxef itself just can be used as active pharmaceutical ingredients and uses.Therefore, flomoxef is required new crystal, and this new crystal does not contain methylene dichloride, more has superiority in preparation.
[means of dealing with problems]
[0005]
As the result who considers that the problems referred to above are conscientiously studied, the present inventor has found to comprise the new solvate of flomoxef crystalline, and has finished the present invention of following detailed description.
(1) hydrate or the hydrate crystal of compound shown in Xia Mian the chemical formula (I):
[Chemical formula 2]
Figure A20058000541500041
(2) according to the hydrate or the hydrate crystal of above-mentioned (1), it is a monohydrate.
(3) according to the hydrate crystal of above-mentioned (1) or (2), it has main peaks in powder x-ray diffraction figure, is positioned at spacing d=8.31, and 7.00,6.11,5.43,4.47,4.35,4.19,4.15,3.95,3.81,3.50,3.32,2.96 (units: dust).
[0006]
(4) the methyl acetate solvate of compound shown in Xia Mian the chemical formula (I) or methyl acetate solvate crystal:
[chemical formula 3]
Figure A20058000541500051
(5) according to the methyl acetate solvate or the methyl acetate solvate crystal of above-mentioned (4), it is 0.5 methyl acetate solvate.
(6) according to the methyl acetate solvate crystal of above-mentioned (4) or (5), it has main peaks in powder x-ray diffraction figure, be positioned at spacing d=10.42,6.32,4.96,4.62,4.56,4.36,4.23,3.97,3.93,3.79,3.47,2.79 (units: dust).
[effect of the present invention]
[0007]
The novel solvent thing of flomoxef of the present invention is crystal preferably, therefore, is being excellent aspect stability and the operability, and is having superiority in preparation.Particularly, hydrate crystal has the possibility that directly is mixed with injectable usefulness preparation with power filling method, because they do not comprise the organic solvent such as methylene dichloride.Further, methyl acetate solvate crystal is compared with the crystal that comprises methylene dichloride, is having superiority aspect safety and the environment, makes that flomoxef can be with the high-level efficiency suitability for industrialized production.In other words, these crystal can be produced intermediate as active pharmaceutical ingredients or its.
[implementing best mode of the present invention]
[0008]
To make an explanation below according to each solvate of the present invention and its crystal.
(1) hydrate
Preferred each the molecule flomoxef of the hydrate of flomoxef comprises a part water.This hydrate is crystal preferably.The main peaks that such crystal preferably has in powder x-ray diffraction figure is positioned at spacing d=8.31,7.00,6.11,5.43,4.47,4.35,4.19,4.15,3.95,3.81,3.50,3.32,2.96 (units: dust) etc., more specifically be presented in the table 1 or Fig. 1 that will be described later.(X-ray diffraction condition determination: used in cathode-ray tube CuK alpha-ray, tube voltage 40Kv, tube current 30mA, dsin θ=n λ (n is an integer, and θ is a diffraction angle)).
In this manual, the value of spacing d is to have high-intensity relatively peak, and it can be selected as main peaks from X-ray peak easily, still, should be appreciated that crystalline structure is necessary to be limited by these values.That is, can comprise peak in addition, above-mentioned peak.Usually, when measuring crystal by x-ray analysis, owing to determining instrument, condition determination, adhere to existence of solvent or the like, (less) measuring error may appear in the peak.Therefore, use when confirming crystalline structure and any crystal property to the similar substantially X-ray diagram of the above-mentioned figure that belongs to the scope of the invention, this less error should be considered.
Above-mentioned hydrate is passable, for example, by dissolving flomoxef under room temperature or warm (preferred about 20 to 40 ℃) condition or according to JP-A 59-139385 or microbiotic magazine (TheJournal of Antibiotics) (April, P466-476,1985) its dichloromethane solvent thing that the method described in obtains is in a spot of soluble solvent.Introduce down a certain amount of water in room temperature or ice-cooled afterwards, the amount of water should be greater than the amount of soluble solvent, then about 0 ℃ to room temperature, preferably stir or leave standstill in about 5 to 25 ℃ temperature, lasting a few hours to one day obtain.The flomoxef of per 1 gram, the usage quantity of soluble solvent be preferably from 0.1 to 10ml, and preferred 0.5 to 5ml, more preferably 1 to 3ml.The flomoxef of per 1 gram, the usage quantity of water be preferably from 1 to 100ml, and preferred 5 to 50ml, more preferably 10 to 30ml.
The example of soluble solvent comprises for example methyl alcohol of alcohols, ethanol, 2-propyl alcohol, 2-methyl cellosolve, ethylene glycol, methyl cellosolve, glycerol and propylene glycol; Ethers is two  alkane for example, tetrahydrofuran (THF), glycol dimethyl ether and Diethylene Glycol-dimethyl ether; Ketone is acetone for example, methyl ethyl ketone, and methyl iso-butyl ketone (MIBK); The ester class is methyl-formiate for example, ethyl formate, propyl formate, methyl acetate, ethyl acetate, propyl acetate, butylacetate, methyl propionate, ethyl propionate; The organic halogenation hydro carbons is methylene dichloride for example, chloroform, tetracol phenixin, 1,2-ethylene dichloride, trichloroethane, chlorobenzene and dichlorobenzene; Nitrile is acetonitrile and propionitrile for example; Dimethyl formamide; Dimethyl sulfoxide (DMSO); N,N-DIMETHYLACETAMIDE; N-Methyl pyrrolidone; Quinoline; Pyridine; And triethylamine.These solvents can be separately or two or more unite use.
Utilize well-known separation method (for instance, filtering centrifugal or similar approach), can from solvent, separate the crystal of acquisition like this, be purified by well-known method (washing, dry air, drying under reduced pressure for instance) afterwards.
Above-mentioned solvate can be dissolved in the warm water by will comprise the flomoxef that obtains or the extraction residue of its organic solvent thing from the reaction soln of flomoxef intermediate deprotection equally, and prepares to a couple of days in 0-10 ℃ of temperature range stirred for several hour.
[0009]
(2) methyl acetate solvate
Preferred each the molecule flomoxef of the methyl acetate solvate of flomoxef comprises 0.5 to 1.0 molecule, preferably comprises the methyl acetate of 0.5 molecule.The methyl acetate solvate is crystal preferably.This crystal preferably has main peaks in powder x-ray diffraction figure, be positioned at spacing d=10.42, and 6.32,4.96,4.62,4.56,4.36,4.23,3.97,3.93,3.79,3.47,2.79 (units: dust) etc., more specifically be presented in the table 3 or Fig. 2 that will be described later.
The methyl acetate solvate can, for example, prepare in order to following method.Warm (preferably about 20 to 40 ℃) down after dissolving flomoxef or its dichloromethane solvent thing, distill solvent in methyl acetate.At warm (preferably about 20 to 40 ℃) down, after the dissolution residual substance, solution stirs under room temperature at 0 ℃ in methyl acetate, continues a few hours to a couple of days.The crystal that is settled out is filtered, and washing is preferably with cold methyl acetate washing, then at air drying.To the flomoxef of per 1 gram, the each usage quantity of first and second methyl acetates is preferably from 0.1 to 20ml, preferably from 0.5 to 15ml, more preferably from 1 to 10ml.To the flomoxef of per 1 gram, the water usage quantity is preferably from 1 to 100ml, preferably from 5 to 50ml, is more preferably from 10 to 30ml.
Above-mentioned methyl acetate solvate also can be with the preparation of above-described method, and promptly the extraction residue of the reaction soln by using flomoxef intermediate deprotection is as starting raw material.
Above-mentioned hydrate or methyl acetate solvate can be converted to other and want the solvate or the crystal that obtain.By freeze drying process, power filling method or the like, preparation can single composition or with the pH regulator agent, stablizer or the like is formed together.Particularly, hydrate has very big advantage in preparation, because it is preferably prepared by power filling method.
[0010]
Reference example 1
[chemical formula 4]
(wherein, Me=methyl; The BH=diphenyl-methyl)
With the flomoxef intermediate (in this compound; protected by diphenyl-methyl for 4 of flomoxef; 3 hydroxyls of tetrazolium are by to the protection of methyl carbobenzoxy-(Cbz)) (405mg) (described (microbiotic magazine (The Journal of Amtibiotics) (April in above-mentioned non-patent document 1; P466-476; 1985))), the mixture of methylene dichloride (2.5ml) and Nitromethane 99Min. (0.5ml) is cooled to-30 ℃, adds the dichloromethane solution (2ml) that contains methyl-phenoxide (0.11ml) and tin tetrachloride (0.17ml) afterwards.After the stirring, the temperature of reaction soln progressively was elevated to-10 ℃ in 3.5 hours.Final reaction soln is dumped into 1N hydrochloric acid, in the mixture of ethyl acetate and methyl ethyl ketone, then isolated organic phase is mixed with sodium bicarbonate aqueous solution, make water become acidity with concentrated hydrochloric acid, the mixture with ethyl acetate and methyl ethyl ketone extracts afterwards.Dried over mgso is used in extract saturated common salt water washing, drying under reduced pressure afterwards, and residue is extracted in the reaction that obtains steeping the dichloromethane solvent thing that comprises flomoxef of last form.
Embodiment 1
Under thermal condition, after residue is extracted in the reaction that obtains in the dissolving 1000mg reference example 1 in 20mL water, solution was stirred 1 day down at 5 ℃.The crystal that is settled out is filtered, use the 10mL cold water washing afterwards.Carry out air drying and drying under reduced pressure (condition: 50Pa, 5 to 10 hours), obtain the flomoxef monohydrate crystal of 803mg (77%).
IR (whiteruss): 3539,3198,2924,2854,1776,1711,1685,1645,1534,1450,1387,1267,1130,1062,1039,997,861,665cm -1
1H NMR (DMSO-d6): δ 3.36 (3H, unimodal), 3.59 (1H, doublet, J=15.3Hz), 3.66 (1H, doublet, J=15.3Hz), 3.73 (2H, triplets, J=5.1Hz), 4.18 (1H, doublet, J=13.5Hz), 4.23 (1H, doublet, J=13.5Hz), 4.31 (2H, triplet, J=5.1Hz), (4.52 2H, unimodal), 5.06 (2H, wide unimodal), 7.30 (1H, triplet, J=56.4Hz), 9.25 (1H, unimodal).Ultimate analysis: for C 15H 18N 6O 7F 2S 2.H 2O
Calculated value: C35.02, H3.92, N16.33, F7.39, S12.46
Measured value: C35.05, H3.93, N16.39, F7.22, S12.32 moisture content
Calculated value (monohydrate): 3.50%
Measure with Ka Er-Fei Sheer moisture titration apparatus (KF): 3.52%
Fusing point: 94 ℃
Powder x-ray diffraction figure is presented among table 1 and Fig. 1.
[table 1]
2θ The d value Relative intensity
10.64 12.64 14.48 16.30 16.56 19.04 19.86 20.40 21.18 21.38 22.48 23.30 23.88 24.62 25.46 25.64 26.86 27.24 28.36 29.62 30.20 31.24 32.36 33.50 33.66 33.84 35.04 35.78 36.20 8.30 7.00 6.11 5.43 5.34 4.66 4.47 4.35 4.19 4.15 3.95 3.81 3.72 3.61 3.50 3.47 3.31 3.27 3.14 3.01 2.96 2.86 2.76 2.67 2.66 2.65 2.56 2.51 2.48 13 10 14 12 4 6 24 17 13 23 13 13 5 5 13 8 20 8 5 6 13 7 5 6 7 6 5 5 6
[0011]
Embodiment 2
Shown in the table 2 under the condition, residue is extracted in the reaction that obtains in the reference example 1 under room temperature or warm situation, be dissolved in the soluble solvent below, under room temperature or ice-cooled condition, add entry then.Be reflected at 5 to 25 ℃ left standstill or stirred for several hour by 1 day.The all crystals that obtains confirms not contain organic solvent through nucleus magnetic resonance like this, confirms it is monohydrate through ultimate analysis.They also show the powder x-ray diffraction figure identical with embodiment 1.
[table 2]
Sequence number Initial crystal Soluble solvent mL Water (mL)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 100mg ″ ″ ″ ″ 1000mg ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ ″ Methyl alcohol 0.2 ethanol 0.2 ethanol 0.3 acetone 0.2-methyl alcohol 2 ethanol 2 2-propyl alcohol 2 2-methyl cellosolves 2 ethylene glycol 2 methyl acetates 2 ethyl acetate 2 oxolanes 2 two  alkane 2 2-Ethyl Methyl Ethers 2 diethylene glycols-dimethyl ether 2 the third 2 methyl ethyl ketone 2 acetonitriles 2 dimethyl sulfoxide (DMSO)s 2 dimethyl formamides 2 dimethylacetylamides 2 1-METHYLPYRROLIDONEs 2 1.3 0.3 0.2 1.3 1.5 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18
Embodiment 3
Residue is extracted in the reaction that obtains in the 1000mg reference example 1 be dissolved under thermal condition in the 5mL methyl acetate, solvent is removed in distillation then.Under thermal condition, residue is dissolved in the methyl acetate of 2mL, stirred 1 day down at 5 ℃ then.The crystal that is settled out is filtered, and the cold methyl acetate with 2mL washs afterwards.After the dry air, obtain 784mg (82%) 0.5 methyl acetate solvate crystal.
IR (whiteruss): 3493,3249,3041,2925,2853,1765,1737,1711,1668,1643,1543,1457,1441,1420,1392,1376,1248,1231,1080,1062,1042,1030,805,751cm -1
1H NMR (DMSO-d6): δ 3.36 (3H, unimodal), 3.59 (1H, doublet, J=15.3Hz), 3.66 (1H, doublet, J=15.3Hz), 3.73 (2H, triplets, J=5.1Hz), 4.18 (1H, doublet, J=13.5Hz), 4.23 (1H, doublet, J=13.5Hz), 4.31 (2H, triplet, J=5.1Hz), (4.51 2H, unimodal), 5.06 (2H, wide unimodal), 7.30 (1H, triplet, J=56.4Hz), 9.25 (1H, unimodal).In NMR, observe the methyl acetate peak 1.98 (3H, unimodal) of 0.5 molecule, 3.55 (3H, unimodal)
Ultimate analysis: for C 15H 18N 6O 7F 2S 2.1/2AcOMe
Calculated value: C37.15, H3.97, N15.75, F7.12, S12.02
Measured value: C36.96, H3.92, N15.55, F6.98, S11.96
Fusing point: 78 ℃
Powder x-ray diffraction figure is presented among table 3 and Fig. 2.
[table 3]
2θ The d value Relative intensity
8.48 11.34 11.70 14.00 16.94 17.86 19.20 19.46 20.00 20.36 21.00 22.36 22.62 23.48 24.50 25.66 26.78 27.02 27.42 27.82 30.80 31.70 32.04 10.42 7.80 7.56 6.32 5.23 4.96 4.62 4.56 4.44 4.36 4.23 3.97 3.93 3.79 3.63 3.47 3.32 3.30 3.25 3.20 2.90 2.82 2.79 38 6 5 10 7 15 14 23 8 33 17 15 12 12 6 18 7 9 6 9 9 8 10
[0012]
Embodiment 4
Residue is extracted in the reaction that obtains in the 1000mg reference example 1 be dissolved under thermal condition in the 5mL methyl acetate, solvent is removed in distillation then.Under thermal condition, residue is dissolved in the methyl acetate of 2mL, stirred 1 day down at 5 ℃ then.The crystal that is settled out is filtered, and the cold methyl acetate with 2mL washs afterwards.After the dry air, obtain 838mg (78%) 0.5 methyl acetate solvate crystal, similar to embodiment 3.
[brief description of drawings]
The powder x-ray diffraction figure of the flomoxef monohydrate crystal that obtains among [Fig. 1] embodiment 1.
The flomoxef 0.5 methyl acetate solvate crystalline powder x-ray diffraction figure that obtains among [Fig. 2] embodiment 3.

Claims (6)

1. the hydrate or the hydrate crystal of compound (I) shown in the following chemical formula
[Chemical formula 1]
Figure A2005800054150002C1
2. according to the hydrate or the hydrate crystal of claim 1, it is a monohydrate.
3. according to the hydrate crystal of claim 1 or 2, it has main peaks in powder x-ray diffraction figure, is positioned at spacing d=8.31, and 7.00,6.11,5.43,4.47,4.35,4.19,4.15,3.95,3.81,3.50,3.32,2.96 (units: dust).
4. methyl acetate solvate of compound (I) shown in the following chemical formula or methyl acetate solvate crystal
[Chemical formula 2]
Figure A2005800054150002C2
5. according to the methyl acetate solvate or the methyl acetate solvate crystal of claim 4, it is 0.5 methyl acetate solvate.
6. according to the acetate formic acid solvent thing crystal of claim 4 or 5, have main peaks among its powder x-ray diffraction figure, be positioned at spacing d=10.42,6.32,4.96,4.62,4.56,4.36,4.23,3.97,3.93,3.79,3.47,2.79 (units: dust).
CNB2005800054157A 2004-02-20 2005-02-18 Crystal of oxacephem Expired - Fee Related CN100509819C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004043824 2004-02-20
JP043824/2004 2004-02-20
JP2004053283 2004-02-27
JP053283/2004 2004-02-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2008101816721A Division CN101440098B (en) 2004-02-20 2005-02-18 Crystal of oxacephem

Publications (2)

Publication Number Publication Date
CN1922191A true CN1922191A (en) 2007-02-28
CN100509819C CN100509819C (en) 2009-07-08

Family

ID=34703384

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005800054157A Expired - Fee Related CN100509819C (en) 2004-02-20 2005-02-18 Crystal of oxacephem
CN2008101816721A Expired - Fee Related CN101440098B (en) 2004-02-20 2005-02-18 Crystal of oxacephem

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008101816721A Expired - Fee Related CN101440098B (en) 2004-02-20 2005-02-18 Crystal of oxacephem

Country Status (5)

Country Link
JP (1) JP4530287B2 (en)
KR (1) KR100832757B1 (en)
CN (2) CN100509819C (en)
TW (1) TWI338008B (en)
WO (1) WO2005058914A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102952149A (en) * 2012-11-09 2013-03-06 浙江新和成股份有限公司 One-pot synthesis method of flomoxef intermediate
CN108424418A (en) * 2017-02-15 2018-08-21 山东致纯医药科技有限公司 A kind of Flomoxef sodium impurity

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680079A4 (en) 2003-10-24 2008-01-02 Adhesives Res Inc Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
KR101314500B1 (en) 2012-12-28 2013-10-07 제일약품주식회사 Oxacephem preparations with improved stability and preparation method thereof
CN105801601B (en) * 2016-04-02 2018-01-26 丽珠医药集团股份有限公司 A kind of Flomoxef Sodium synthetic method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59139385A (en) * 1982-12-23 1984-08-10 Shionogi & Co Ltd Fluoromethylthiooxacephalosporin
JPS59231090A (en) * 1983-06-14 1984-12-25 Shionogi & Co Ltd Fluoromethylthioxacephalosporin
JPH03279329A (en) * 1990-03-27 1991-12-10 Banyu Pharmaceut Co Ltd Antibiotic comprising cephamycin and cephalosporin
JP3279329B2 (en) * 1991-11-01 2002-04-30 クルップ・プレスタ・アーゲー Camshaft manufacturing equipment

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102952149A (en) * 2012-11-09 2013-03-06 浙江新和成股份有限公司 One-pot synthesis method of flomoxef intermediate
CN102952149B (en) * 2012-11-09 2015-06-24 浙江新和成股份有限公司 One-pot synthesis method of flomoxef intermediate
CN108424418A (en) * 2017-02-15 2018-08-21 山东致纯医药科技有限公司 A kind of Flomoxef sodium impurity

Also Published As

Publication number Publication date
KR20060120253A (en) 2006-11-24
WO2005058914A1 (en) 2005-06-30
TW200533672A (en) 2005-10-16
JPWO2005058914A1 (en) 2007-07-12
KR100832757B1 (en) 2008-05-27
TWI338008B (en) 2011-03-01
CN100509819C (en) 2009-07-08
JP4530287B2 (en) 2010-08-25
CN101440098A (en) 2009-05-27
CN101440098B (en) 2011-07-13

Similar Documents

Publication Publication Date Title
WO2018031535A1 (en) Solid state forms of lumateperone ditosylate salt
CN1922191A (en) Crystal of oxacephem
CN1845917A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicam
CN102686594A (en) Polymorphs of darunavir
CN1475477A (en) Method and intermdeiate used for manufacturing antifolic acid agent
EP3515890A1 (en) New crystal forms of lenvatinib
US20200190056A1 (en) Processes for the preparation of niraparib and intermediates thereof
CN1705640A (en) Ionic liquids containing a sulfonate anion
WO2013098773A1 (en) Crystalline forms of pitavastatin calcium
CN1388807A (en) Penicillin crystal and process for producing the same
WO2009149053A2 (en) Naproxcinod process and solid dispersion
US8138343B2 (en) Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
EP3317251A1 (en) Polymer additive and a method for the production thereof
CN104530112A (en) Method for preparing everolimus intermediate and ethylated impurities thereof
EP3002286B1 (en) Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof
US20140378472A1 (en) Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
JP2010132561A (en) New type a crystal of cibenzoline succinate and method for producing the same
CN101277959A (en) Process for preparing zolpidem hemitartrate and tartrate polymorphs
CN1278253A (en) Process for producing substituted alkylamines or salts thereof
CN1777586A (en) Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
CN1882526A (en) Process for the preparation of voglibose
CN1095846C (en) Production process of cephem compound
CN1467209A (en) 4,6-dihydrofuran [3,4-d] imidazole-6- ketone derivative and salt and preparation method thereof
CN111533706A (en) Preparation method of 1,4, 6-trisubstituted 1, 2-dihydro-triazine compound
CN1251096A (en) 1,3-di-substituted 2-nitroguanidines prepn. method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090708

Termination date: 20210218

CF01 Termination of patent right due to non-payment of annual fee